Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

228 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
Cortés J, Dieras V, Ro J, Barriere J, Bachelot T, Hurvitz S, Le Rhun E, Espié M, Kim SB, Schneeweiss A, Sohn JH, Nabholtz JM, Kellokumpu-Lehtinen PL, Taguchi J, Piacentini F, Ciruelos E, Bono P, Ould-Kaci M, Roux F, Joensuu H. Cortés J, et al. Among authors: le rhun e. Lancet Oncol. 2015 Dec;16(16):1700-10. doi: 10.1016/S1470-2045(15)00373-3. Epub 2015 Nov 17. Lancet Oncol. 2015. PMID: 26596672 Clinical Trial.
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.
Bachelot T, Romieu G, Campone M, Diéras V, Cropet C, Dalenc F, Jimenez M, Le Rhun E, Pierga JY, Gonçalves A, Leheurteur M, Domont J, Gutierrez M, Curé H, Ferrero JM, Labbe-Devilliers C. Bachelot T, et al. Among authors: le rhun e. Lancet Oncol. 2013 Jan;14(1):64-71. doi: 10.1016/S1470-2045(12)70432-1. Epub 2012 Nov 2. Lancet Oncol. 2013. PMID: 23122784 Clinical Trial.
Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial.
Pierga JY, Bidard FC, Cropet C, Tresca P, Dalenc F, Romieu G, Campone M, Mahier Aït-Oukhatar C, Le Rhun E, Gonçalves A, Leheurteur M, Dômont J, Gutierrez M, Curé H, Ferrero JM, Labbe-Devilliers C, Bachelot T. Pierga JY, et al. Among authors: le rhun e. Ann Oncol. 2013 Dec;24(12):2999-3004. doi: 10.1093/annonc/mdt348. Epub 2013 Sep 6. Ann Oncol. 2013. PMID: 24013510 Free article. Clinical Trial.
Treatment patterns, clinical outcomes and health care costs associated with HER2-positive breast cancer with central nervous system metastases: a French multicentre observational study.
Baffert S, Cottu P, Kirova YM, Mercier F, Simondi C, Bachelot T, Le Rhun E, Levy C, Gutierrez M, Madranges N, Moldovan C, Coudert B, Spaëth D, Serin D, Cotté FE, Benjamin L, Maillard C, Laulhere-Vigneau S, Durand-Zaleski I. Baffert S, et al. Among authors: le rhun e. BMC Health Serv Res. 2013 Oct 31;13:456. doi: 10.1186/1472-6963-13-456. BMC Health Serv Res. 2013. PMID: 24176086 Free PMC article.
CSF CA 15-3 in breast cancer-related leptomeningeal metastases.
Le Rhun E, Kramar A, Salingue S, Girot M, Rodrigues I, Mailliez A, Zairi F, Bakhache E, Robin YM, Taillibert S, Dubois F, Bonneterre J, Chamberlain MC. Le Rhun E, et al. J Neurooncol. 2014 Mar;117(1):117-24. doi: 10.1007/s11060-014-1361-1. Epub 2014 Jan 28. J Neurooncol. 2014. PMID: 24469852 Clinical Trial.
228 results